The YODA Project Research Proposal Due Diligence Assessment

Part 1: General Information		
YODA Project (Protocol) ID:	2017-2511	
Date:	27 November 2017	
Product Name:	Canagliflozin	
Therapeutic Area:	Metabolism	
Product Class:	SGLT-2 inhibitor	
Condition(s) Studied:	Type 2 Diabetes	
Protocol Number(s) and Title(s):	NCT00968812 - A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy	
Part 2: Data Availability		
	Question:	Response:
Data Holder has authority to p partner has agreed to share cli	rovide clinical trial data or development	Yes
Comments: N/A		
Data Holder has sharable electronic clinical trial data or data can be converted		Yes
to electronic format.		
Comments: N/A		
De-identification and redaction of clinical trial data in accordance with current		Yes
HIPAA and EU criteria allows protection of participant privacy and confidentiality.		
Comments: N/A		
The product and relevant indication studied has either been approved by Yes		
regulators in the US and EU, or terminated from development.		
Comments: N/A		
Data Holder has completed the clinical trial and trial has been completed for a Yes		
period of at least 18 months (or results published in peer-reviewed		
biomedical literature).		
Comments: N/A		
Part 3: Data Availability Summary		
Based on the responses to the above Data Availability questions, the Yes requested clinical trial data can be made available for data sharing.		Yes
Part 4: Proposal Review		
Question: Response:		
Summary-level CSR data is appropriate for the proposed analysis.		Yes
Participant-level data is appropriate for the proposed analysis.		No
A similar analysis is underway or completed/pending disclosure by Janssen. Yes		
Comments: Analysis of change in A1c from baseline to Week 52 as well as analyses of proportion of		
patients reaching A1c < 7% have been conducted by Janssen and reported in CSR		